Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Mol Cancer Res ; 14(6): 518-27, 2016 06.
Article in English | MEDLINE | ID: mdl-27001765

ABSTRACT

UNLABELLED: Recent evidence indicates that cancer cells, even in the absence of a primary tumor, recirculate from established secondary lesions to further seed and colonize skeleton and soft tissues, thus expanding metastatic dissemination and precipitating the clinical progression to terminal disease. Recently, we reported that breast cancer cells utilize the chemokine receptor CX3CR1 to exit the blood circulation and lodge to the skeleton of experimental animals. Now, we show that CX3CR1 is overexpressed in human breast tumors and skeletal metastases. To assess the clinical potential of targeting CX3CR1 in breast cancer, a functional role of CX3CR1 in metastatic seeding and progression was first validated using a neutralizing antibody for this receptor and transcriptional suppression by CRISPR interference (CRISPRi). Successively, we synthesized and characterized JMS-17-2, a potent and selective small-molecule antagonist of CX3CR1, which was used in preclinical animal models of seeding and established metastasis. Importantly, counteracting CX3CR1 activation impairs the lodging of circulating tumor cells to the skeleton and soft-tissue organs and also negatively affects further growth of established metastases. Furthermore, nine genes were identified that were similarly altered by JMS-17-2 and CRISPRi and could sustain CX3CR1 prometastatic activity. In conclusion, these data support the drug development of CX3CR1 antagonists, and promoting their clinical use will provide novel and effective tools to prevent or contain the progression of metastatic disease in breast cancer patients. IMPLICATIONS: This work conclusively validates the instrumental role of CX3CR1 in the seeding of circulating cancer cells and is expected to pave the way for pairing novel inhibitors of this receptor with current standards of care for the treatment of breast cancer patients. Mol Cancer Res; 14(6); 518-27. ©2016 AACR.


Subject(s)
Breast Neoplasms/drug therapy , Receptors, Chemokine/antagonists & inhibitors , Small Molecule Libraries/pharmacology , Animals , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , CX3C Chemokine Receptor 1 , Cell Line, Tumor , Female , Humans , Mice
2.
Transl Oncol ; 8(5): 358-367, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26500026

ABSTRACT

Inflammatory breast cancer (IBC) is an aggressive and invasive tumor, accounting for 2.5% of all breast cancer cases, and characterized by rapid progression, regional and distant metastases, younger age of onset, and lower overall survival. Presently, there are no effective therapies against IBC and a paucity of model systems. Our aim was to develop a clinically relevant IBC model that would allow investigations on the role of chemokine receptors in IBC metastasis. Primary cultures of tumor cells were isolated from pleural exudates of an IBC patient and grown as spheres or monolayers. We developed a human xenograft model where patient-derived IBC cells, stably transduced with lentiviral vectors expressing fluorescent and bioluminescent markers, were inoculated directly into the left ventricle of mice. Our in vivo data show that these IBC cells (FC-IBC02A) are able to seed and proliferate into various organs, including brain, lungs, lymph nodes, and bone, closely replicating the metastatic spread observed in IBC patients. Moreover, cells were able to generate tumors when grafted in the mammary fat pad of mice. RT-PCR and microscopy studies revealed expression of both CXCR4 and ACKR3 receptors in FC-IBC02A cells. Furthermore, CXCL12 (the endogenous chemokine ligand of these receptors) induced transendothelial migration of these cells and stimulated signaling pathways involved in cell survival and migration - an effect reduced by CXCR4 or ACKR3 antagonists. This new model can be used to develop chemokine-based pharmacological approaches against the IBC metastatic process. This work also provides the first evidence of ACKR3 expression in IBC cells.

3.
Mol Cancer Res ; 13(9): 1336-46, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26023164

ABSTRACT

UNLABELLED: The bone is a preferred site for metastatic homing of prostate cancer cells. Once prostate cancer patients develop skeletal metastases, they eventually succumb to the disease; therefore, it is imperative to identify key molecular drivers of this process. This study examines the involvement of protein kinase C epsilon (PKCε), an oncogenic protein that is abnormally overexpressed in human tumor specimens and cell lines, on prostate cancer cell bone metastasis. PC3-ML cells, a highly invasive prostate cancer PC3 derivative with bone metastatic colonization properties, failed to induce skeletal metastatic foci upon inoculation into nude mice when PKCε expression was silenced using shRNA. Interestingly, while PKCε depletion had only marginal effects on the proliferative, adhesive, and migratory capacities of PC3-ML cells in vitro or in the growth of xenografts upon s.c. inoculation, it caused a significant reduction in cell invasiveness. Notably, PKCε was required for transendothelial cell migration (TEM) as well as for the growth of PC3-ML cells in a bone biomimetic environment. At a mechanistic level, PKCε depletion abrogates the expression of IL1ß, a cytokine implicated in skeletal metastasis. Taken together, PKCε is a key factor for driving the formation of bone metastasis by prostate cancer cells and is a potential therapeutic target for advanced stages of the disease. IMPLICATIONS: This study uncovers an important new function of PKCε in the dissemination of cancer cells to the bone; thus, highlighting the promising potential of this oncogenic kinase as a therapeutic target for skeletal metastasis.


Subject(s)
Bone Neoplasms/secondary , Mediator Complex , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Protein Kinase C-epsilon/metabolism , Animals , Cell Adhesion , Cell Line, Tumor , Cell Movement , Cell Proliferation , Heterografts , Humans , Interleukin-1beta/metabolism , Male , Mice , Mice, Nude , RNA, Small Interfering/metabolism
4.
J Clin Invest ; 123(7): 2907-20, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23921130

ABSTRACT

Metabolic reprogramming is an important driver of tumor progression; however, the metabolic regulators of tumor cell motility and metastasis are not understood. Here, we show that tumors maintain energy production under nutrient deprivation through the function of HSP90 chaperones compartmentalized in mitochondria. Using cancer cell lines, we found that mitochondrial HSP90 proteins, including tumor necrosis factor receptor-associated protein-1 (TRAP-1), dampen the activation of the nutrient-sensing AMPK and its substrate UNC-51-like kinase (ULK1), preserve cytoskeletal dynamics, and release the cell motility effector focal adhesion kinase (FAK) from inhibition by the autophagy initiator FIP200. In turn, this results in enhanced tumor cell invasion in low nutrients and metastatic dissemination to bone or liver in disease models in mice. Moreover, we found that phosphorylated ULK1 levels were correlated with shortened overall survival in patients with non-small cell lung cancer. These results demonstrate that mitochondrial HSP90 chaperones, including TRAP-1, overcome metabolic stress and promote tumor cell metastasis by limiting the activation of the nutrient sensor AMPK and preventing autophagy.


Subject(s)
Bone Neoplasms/metabolism , Carcinoma, Non-Small-Cell Lung/metabolism , Cytoskeleton/metabolism , Liver Neoplasms, Experimental/metabolism , Lung Neoplasms/metabolism , Stress, Physiological , Adenylate Kinase/metabolism , Animals , Antineoplastic Agents/pharmacology , Autophagy-Related Protein-1 Homolog , Bone Neoplasms/secondary , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/secondary , Cell Line, Tumor , Cell Movement , Female , Gene Knockdown Techniques , Guanidines/pharmacology , HSP90 Heat-Shock Proteins/genetics , HSP90 Heat-Shock Proteins/metabolism , Hexokinase/metabolism , Humans , Intracellular Signaling Peptides and Proteins/genetics , Intracellular Signaling Peptides and Proteins/metabolism , Kaplan-Meier Estimate , Lactams, Macrocyclic/pharmacology , Liver Neoplasms, Experimental/secondary , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Mice , Mice, SCID , Mitochondria/metabolism , Mitochondrial Membranes/enzymology , NIH 3T3 Cells , Neoplasm Transplantation , Phosphorylation , Protein Processing, Post-Translational , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , RNA, Small Interfering/genetics
5.
Cancer Res ; 73(11): 3297-305, 2013 Jun 01.
Article in English | MEDLINE | ID: mdl-23536554

ABSTRACT

Despite the progress made in the early detection and treatment of prostate adenocarcinoma, the metastatic lesions from this tumor are incurable. We used genome-wide expression analysis of human prostate cancer cells with different metastatic behavior in animal models to reveal that bone-tropic phenotypes upregulate three genes encoding for the cytokine interleukin-1ß (IL-1ß), the chemokine CXCL6 (GCP-2), and the protease inhibitor elafin (PI3). The Oncomine database revealed that these three genes are significantly upregulated in human prostate cancer versus normal tissue and correlate with Gleason scores ≥7. This correlation was further validated for IL-1ß by immunodetection in prostate tissue arrays. Our study also shows that the exogenous overexpression of IL-1ß in nonmetastatic cancer cells promotes their growth into large skeletal lesions in mice, whereas its knockdown significantly impairs the bone progression of highly metastatic cells. In addition, IL-1ß secreted by metastatic cells induced the overexpression of COX-2 (PTGS2) in human bone mesenchymal cells treated with conditioned media from bone metastatic prostate cancer cells. Finally, we inspected human tissue specimens from skeletal metastases and detected prostate cancer cells positive for both IL-1ß and synaptophysin while concurrently lacking prostate-specific antigen (PSA, KLK3) expression. Collectively, these findings indicate that IL-1ß supports the skeletal colonization and metastatic progression of prostate cancer cells with an acquired neuroendocrine phenotype.


Subject(s)
Bone Neoplasms/secondary , Carcinoma, Neuroendocrine/pathology , Interleukin-1beta/biosynthesis , Prostatic Neoplasms/pathology , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Animals , Bone Neoplasms/genetics , Bone Neoplasms/metabolism , Carcinoma, Neuroendocrine/genetics , Carcinoma, Neuroendocrine/metabolism , Cell Line, Tumor , Disease Progression , Gene Expression Regulation, Neoplastic , Heterografts , Humans , Immunocompromised Host , Interleukin-1beta/genetics , Male , Mice , NIH 3T3 Cells , Neuroendocrine Cells/metabolism , Neuroendocrine Cells/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Receptor, Platelet-Derived Growth Factor alpha/genetics , Receptor, Platelet-Derived Growth Factor alpha/metabolism , Synaptophysin/biosynthesis , Up-Regulation
6.
Cancer Res ; 73(10): 3155-67, 2013 May 15.
Article in English | MEDLINE | ID: mdl-23536555

ABSTRACT

The molecular mechanisms underlying metastatic dissemination are still not completely understood. We have recently shown that ß(1) integrin-dependent cell adhesion to fibronectin and signaling is affected by a transmembrane molecule, Trop-2, which is frequently upregulated in human carcinomas. Here, we report that Trop-2 promotes metastatic dissemination of prostate cancer cells in vivo and is abundantly expressed in metastasis from human prostate cancer. We also show here that Trop-2 promotes prostate cancer cell migration on fibronectin, a phenomenon dependent on ß(1) integrins. Mechanistically, we demonstrate that Trop-2 and the α(5)ß(1) integrin associate through their extracellular domains, causing relocalization of α(5)ß(1) and the ß(1)-associated molecule talin from focal adhesions to the leading edges. Trop-2 effect is specific as this molecule does not modulate migration on vitronectin, does not associate with the major vitronectin receptor, α(v)ß(3) integrin, and does not affect localization of α(v)ß(3) integrin as well as vinculin in focal adhesions. We show that Trop-2 enhances directional prostate cancer cell migration, through modulation of Rac1 GTPase activity. Finally, we show that Trop-2 induces activation of PAK4, a kinase that has been reported to mediate cancer cell migration. In conclusion, we provide the first evidence that ß(1) integrin-dependent migratory and metastatic competence of prostate cancer cells is enhanced by Trop-2.


Subject(s)
Antigens, Neoplasm/physiology , Cell Adhesion Molecules/physiology , Integrin beta1/physiology , Prostatic Neoplasms/pathology , Animals , Cell Line, Tumor , Cell Movement , Humans , Male , Mice , Neoplasm Metastasis , Protein Multimerization , Receptors, Vitronectin/physiology
7.
J Clin Invest ; 123(1): 493-508, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23257359

ABSTRACT

Cyclin D1b is a splice variant of the cell cycle regulator cyclin D1 and is known to harbor divergent and highly oncogenic functions in human cancer. While cyclin D1b is induced during disease progression in many cancer types, the mechanisms underlying cyclin D1b function remain poorly understood. Herein, cell and human tumor xenograft models of prostate cancer were utilized to resolve the downstream pathways that are required for the protumorigenic functions of cyclin D1b. Specifically, cyclin D1b was found to modulate the expression of a large transcriptional network that cooperates with androgen receptor (AR) signaling to enhance tumor cell growth and invasive potential. Notably, cyclin D1b promoted AR-dependent activation of genes associated with metastatic phenotypes. Further exploration determined that transcriptional induction of SNAI2 (Slug) was essential for cyclin D1b-mediated proliferative and invasive properties, implicating Slug as a critical driver of disease progression. Importantly, cyclin D1b expression highly correlated with that of Slug in clinical samples of advanced disease. In vivo analyses provided strong evidence that Slug enhances both tumor growth and metastatic phenotypes. Collectively, these findings reveal the underpinning mechanisms behind the protumorigenic functions of cyclin D1b and demonstrate that the convergence of the cyclin D1b/AR and Slug pathways results in the activation of processes critical for the promotion of lethal tumor phenotypes.


Subject(s)
Cyclin D1/metabolism , Prostatic Neoplasms/metabolism , Receptors, Androgen/metabolism , Signal Transduction , Transcription Factors/metabolism , Alternative Splicing/genetics , Animals , Cyclin D1/genetics , Gene Expression Regulation, Neoplastic/genetics , Humans , Male , Mice , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Transplantation , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Receptors, Androgen/genetics , Snail Family Transcription Factors , Transcription Factors/genetics , Transcriptional Activation/genetics , Transplantation, Heterologous
8.
Int J Cancer ; 131(7): E1055-66, 2012 Oct 01.
Article in English | MEDLINE | ID: mdl-22467332

ABSTRACT

Recent studies suggest that peroxisome proliferator-activated receptor gamma (PPARγ) agonists may have cancer chemopreventive activity. Other studies have shown that loss of epidermal PPARγ results in enhanced chemical carcinogenesis in mice via unknown mechanisms. However, ultraviolet B (UVB) exposure represents the primary etiological agent for skin cancer formation and the role of PPARγ in photobiology and photocarcinogenesis is unknown. In previous studies, we demonstrated that UVB irradiation of cells results in the formation of oxidized glycerophosphocholines that exhibit PPARγ ligand activity. We therefore hypothesized that PPARγ would prove to be a chemopreventive target in photocarcinogenesis. We first showed that UVB irradiation of mouse skin causes generation of PPARγ agonist species in vivo. We then generated SKH-1 hairless, albino mice deficient in epidermal Pparg (Pparg-/-(epi)) using a cytokeratin 14 driven Cre-LoxP strategy. Using a chronic model of UVB photocarcinogenesis, we next showed that Pparg-/-(epi) mice exhibit an earlier onset of tumor formation, increased tumor burden and tumor progression. Increased tumor burden in Pparg-/-(epi) mice was accompanied by a significant increase in epidermal hyperplasia and p53 positive epidermal cells in surrounding skin lacking tumors. After acute UVB irradiation, Pparg-/-(epi) mice exhibited an augmentation of both UVB-induced Caspase 3/7 activity and inflammation. Increased apoptosis and inflammation was also observed after treatment with the PPARγ antagonist GW9662. With chronic UVB irradiation, Pparg-/-(epi) mice exhibited a sustained increase in erythema and transepidermal water loss relative to wildtype littermates. This suggests that PPARγ agonists could have possible chemopreventive activity in non-melanoma skin cancer.


Subject(s)
Apoptosis/radiation effects , Cell Transformation, Neoplastic , Epidermis/metabolism , Epidermis/radiation effects , PPAR gamma/genetics , Skin Neoplasms/metabolism , Ultraviolet Rays/adverse effects , Animals , Caspase 3/metabolism , Caspase 7/metabolism , Cell Transformation, Neoplastic/drug effects , Cell Transformation, Neoplastic/genetics , Epidermis/pathology , Erythema/metabolism , Erythema/pathology , Female , Hyperplasia , Inflammation/metabolism , Inflammation/pathology , Keratinocytes/metabolism , Keratinocytes/pathology , Ligands , Mice , Mice, Hairless , Mice, Knockout , PPAR gamma/deficiency , Skin Neoplasms/pathology , Tumor Burden , Tumor Suppressor Protein p53/metabolism
9.
Chin J Cancer ; 30(9): 612-9, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21880182

ABSTRACT

Metastasis represents by far the most feared complication of prostate carcinoma and is the main cause of death for patients. The skeleton is frequently targeted by disseminated cancer cells and represents the sole site of spread in more than 80% of prostate cancer cases. Compatibility between select malignant phenotypes and the microenvironment of colonized tissues is broadly recognized as the culprit for the organ-tropism of cancer cells. Here, we review our recent studies showing that the expression of platelet-derived growth factor receptor alpha (PDGFRα) supports the survival and growth of prostate cancer cells in the skeleton and that the soluble fraction of bone marrow activates PDGFRα in a ligand-independent fashion. Finally, we offer pre-clinical evidence that this receptor is a viable target for therapy.


Subject(s)
Bone Marrow/enzymology , Bone Neoplasms/secondary , Prostatic Neoplasms/enzymology , Receptor, Platelet-Derived Growth Factor alpha/metabolism , Animals , Antibodies, Monoclonal/therapeutic use , Bone Marrow/pathology , Bone Neoplasms/prevention & control , Enzyme Activation , Humans , Male , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Receptor, Platelet-Derived Growth Factor alpha/antagonists & inhibitors , Receptor, Platelet-Derived Growth Factor alpha/genetics , Receptor, Platelet-Derived Growth Factor alpha/immunology , Signal Transduction , Transcriptional Activation
10.
PPAR Res ; 2010: 467053, 2010.
Article in English | MEDLINE | ID: mdl-20508724

ABSTRACT

Studies using PPARgamma agonists in mouse skin have suggested that peroxisome proliferator-activated receptor gamma (PPARgamma) is irrelevant to cutaneous photobiology. However, in several epithelial cell lines, ultraviolet B (UVB) has been shown to induce the nonenzymatic production of oxidized phospholipids that act as PPARgamma agonists. UVB is also a potent inducer of prostaglandin E(2) (PGE(2)) production and COX-2 expression in keratinocytes and PPARgamma is coupled to increased PGE(2) production in other cell lines. In this current study, we demonstrate that PPARgamma agonists, but not PPARalpha or PPARbeta/delta agonists, induce PGE(2) production and COX-2 expression in primary human keratinocytes (PHKs). Importantly, PPARgamma agonist-induced COX-2 expression and PGE(2) production were partially inhibited by the PPARgamma antagonist, GW9662, indicating that both PPARgamma-dependent and -independent pathways are likely involved. GW9662 also suppressed UVB and tert-butylhydroperoxide- (TBH-) induced PGE(2) production in PHKs and intact human epidermis and partially inhibited UVB-induced COX-2 expression in PHKs. These findings provide evidence that PPARgamma is relevant to cutaneous photobiology in human epidermis.

SELECTION OF CITATIONS
SEARCH DETAIL
...